Integra LifeSciences Announces Three-Year Contract With Novation to Provide Jarit(R) Sterilization Containers
April 04 2011 - 6:00AM
Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced
today that it has signed a three-year contract with Novation, the
leading healthcare supply contracting company, to provide Jarit®
sterilization containers to the members of VHA Inc, University
HealthSystem Consortium (UHC) and Provista.
"We are pleased that Novation has selected Integra as a
contracted supplier of our sterilization containers," said Dan
Reuvers, President, Integra Surgical. "By adding containers as a
companion to our previously-contracted instruments, we look forward
to limiting uncertainty for the members served by Novation by
helping them ensure that their instruments are sterilized and cared
for in the optimal way."
Integra is a leading provider of surgical instruments used in
general surgery, neurosurgery, cardiac surgery and most other
surgical modalities, as well as surgical retractor systems and
illumination products. Integra's brands include recognized
names like Luxtec®, Jarit®, Miltex®, Ruggles™, and Omni-Tract®.
About Integra LifeSciences
Integra LifeSciences, a world leader in medical devices, is
dedicated to limiting uncertainty for surgeons, so they can
concentrate on providing the best patient care. Integra offers
innovative solutions in orthopedics, neurosurgery, spine,
reconstructive and general surgery. For more information, please
visit www.integralife.com.
About Novation
Novation is the leading health care supply contracting company
for more than 25,000 members of VHA Inc. and the University
HealthSystem Consortium (UHC), two national health care alliances,
and 5,500 members of Provista, LLC, representing 28,000 sites.
Novation provides alliance members contract and price management
and spend management services. Based in Irving, Texas, Novation
develops and manages competitive contracts with more than 600
suppliers.
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include, but are not limited
to, statements concerning the products and services provided by
Integra. Such forward looking statements involve risks and
uncertainties that could cause actual results to differ materially
from predicted or expected results. Among other things, the
willingness of surgical professionals to use Integra products may
affect the prospects for their use in surgical procedures. In
addition, the economic, competitive, governmental, technological
and other factors, identified under the heading "Risk Factors"
included in Item IA of Integra's Annual Report on Form 10-K for the
year ended December 31, 2010 and information contained in
subsequent filings with the Securities and Exchange Commission
could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation
Gianna Sabella
Director, Corporate Communications
(609) 936-2389
gianna.sabella@integralife.com
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From May 2024 to Jun 2024
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Jun 2023 to Jun 2024